To answer the question of what is the best first-line strategy in patients with BRAF-mutated metastatic melanoma between target therapies and immunotherapy, many phase III studies are ongoing and results are pending [e.g., Secombit (10), Dreamseq (9)]. Here, BRAF is linked to metastatic melanoma.